Bilateral anterior uveitis after immunotherapy for malignant melanoma

• Main Authors: Chia-Jui Chang, Shih-Jen Chen, De-Kuang Hwang, Catherine Jui-Ling Liu
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2018-01-01
• Series: Taiwan Journal of Ophthalmology
• Subjects: Immune checkpoint blockade; ipilimumab; pembrolizumab; uveitis
• Online Access: http://www.e-tjo.org/article.asp?issn=2211-5056;year=2018;volume=8;issue=3;spage=173;epage=175;aulast=Chang

Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior uveitis after immune checkpoint blockade therapy with pembrolizumab and ipilimumab for malignant melanoma. His symptoms and signs improved after topical treatment with corticosteroids. Clinicians should be aware that uveitis can be an immune-related adverse event of immunotherapy.